Emergent BioSolutions Inc
EBS12.430USD
-0.200-1.58%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
655.06MCap. mercado
8.75P/E TTM
Más Datos de Emergent BioSolutions Inc Compañía
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Información de Emergent BioSolutions Inc
Símbolo de cotizaciónEBS
Nombre de la empresaEmergent BioSolutions Inc
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoPapa (Joseph C)
Número de empleados900
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 15
Dirección300 Professional Dr
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal20879
Teléfono12406313200
Sitio Webhttps://emergentbiosolutions.com/
Símbolo de cotizaciónEBS
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoPapa (Joseph C)
Ejecutivos de Emergent BioSolutions Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
68.39K
+1061.66%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
68.25K
+101.64%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
66.14K
-10.60%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
62.55K
-0.97%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
Por regiónUSD
Nombre
Ganancia
Proporción
Non-U.S Government
83.10M
58.98%
U.S.Government
57.80M
41.02%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
Otro
72.56%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
Otro
72.56%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
34.85%
Investment Advisor/Hedge Fund
30.34%
Hedge Fund
7.25%
Individual Investor
2.97%
Research Firm
1.58%
Pension Fund
1.08%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.18%
Family Office
0.07%
Otro
20.85%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
378
39.86M
83.14%
+128.30K
2025Q3
417
39.73M
84.87%
+2.04M
2025Q2
439
37.58M
87.40%
+1.14M
2025Q1
454
36.44M
84.55%
-9.64M
2024Q4
461
35.04M
82.31%
+2.84M
2024Q3
467
32.21M
81.37%
+1.29M
2024Q2
485
30.86M
99.60%
-5.54M
2024Q1
494
36.44M
103.37%
-17.72M
2023Q4
512
41.89M
103.68%
-1.06M
2023Q3
563
42.52M
113.85%
-6.21M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
3.83M
7.18%
+2.25M
+141.83%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
6.72%
+370.21K
+11.52%
Jun 30, 2025
State Street Investment Management (US)
1.74M
3.26%
+30.01K
+1.75%
Jun 30, 2025
American Century Investment Management, Inc.
2.29M
4.3%
-5.46K
-0.24%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.85M
3.47%
+252.40K
+15.81%
Jun 30, 2025
Palisade Capital Management, LLC
1.10M
2.06%
-41.83K
-3.66%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
1.11M
2.07%
+521.91K
+89.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
2.4%
+666.71K
+108.89%
Jun 30, 2025
Acadian Asset Management LLC
974.59K
1.83%
+141.27K
+16.95%
Jun 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
986.67K
1.85%
+55.05K
+5.91%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
AdvisorShares Insider Advantage ETF
0.97%
Royce Quant Small-Cap Quality Value ETF
0.41%
State Street SPDR S&P Biotech ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.23%
Harbor Human Capital Factor US Small Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
Pacer US Small Cap Cash Cows ETF
0.16%
Invesco RAFI US 1500 Small-Mid ETF
0.15%
Avantis US Small Cap Value ETF
0.14%
iShares Micro-Cap ETF
0.13%
Ver más
AdvisorShares Insider Advantage ETF
Proporción0.97%
Royce Quant Small-Cap Quality Value ETF
Proporción0.41%
State Street SPDR S&P Biotech ETF
Proporción0.28%
Federated Hermes MDT Small Cap Core ETF
Proporción0.23%
Harbor Human Capital Factor US Small Cap ETF
Proporción0.19%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.18%
Pacer US Small Cap Cash Cows ETF
Proporción0.16%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.15%
Avantis US Small Cap Value ETF
Proporción0.14%
iShares Micro-Cap ETF
Proporción0.13%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Emergent BioSolutions Inc?
Los cinco principales accionistas de Emergent BioSolutions Inc son:
BlackRock Institutional Trust Company, N.A. posee 3.83M acciones, lo que representa el 7.18% del total de acciones.
The Vanguard Group, Inc. posee 3.58M acciones, lo que representa el 6.72% del total de acciones.
State Street Investment Management (US) posee 1.74M acciones, lo que representa el 3.26% del total de acciones.
American Century Investment Management, Inc. posee 2.29M acciones, lo que representa el 4.30% del total de acciones.
Dimensional Fund Advisors, L.P. posee 1.85M acciones, lo que representa el 3.47% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 3.83M acciones, lo que representa el 7.18% del total de acciones.
The Vanguard Group, Inc. posee 3.58M acciones, lo que representa el 6.72% del total de acciones.
State Street Investment Management (US) posee 1.74M acciones, lo que representa el 3.26% del total de acciones.
American Century Investment Management, Inc. posee 2.29M acciones, lo que representa el 4.30% del total de acciones.
Dimensional Fund Advisors, L.P. posee 1.85M acciones, lo que representa el 3.47% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Emergent BioSolutions Inc?
Los tres principales tipos de accionista de Emergent BioSolutions Inc son:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Emergent BioSolutions Inc (EBS)?
A fecha de 2025Q4, 378 instituciones poseen acciones de Emergent BioSolutions Inc, con un valor de mercado combinado de aproximadamente 39.86M, lo que representa el 83.14% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -1.74%.
¿Cuál es la mayor fuente de ganancias de Emergent BioSolutions Inc?
El FY2025Q2, el segmento empresarial Commercial Product sales generó la ganancia más alta para Emergent BioSolutions Inc, ascendiendo a 67.50M y representando el 47.91% de la ganancia total.
